Vice President, Clinical Development, Neurology at BlueRock Therapeutics

Cambridge, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Cell TherapyIndustries

Requirements

Advanced degree in medicine, life sciences, or related field (implied for VP-level clinical leadership role)
Extensive experience in clinical development, particularly in neurology, neurodegenerative disorders, or cell/gene therapy
Proven track record leading clinical programs from IND-enabling studies through regulatory submissions (IND, BLA)
Expertise as a clinical expert and thought leader in neurology clinical development
Experience building and leading cross-functional teams in a matrixed environment
Strong network with academic collaborators, investigators, and thought leaders in neurology, cell/gene therapy, and translational medicine
Ability to represent the company at scientific and medical conferences

Responsibilities

Provide strategic and operational leadership for BlueRock’s neurology pipeline, including bemdaneprocel (DA01), DA02, MG0X, and future programs targeting Parkinson’s disease and other neurodegenerative disorders
Serve as the primary clinical expert and thought leader internally and externally for neurology clinical development
Design and oversee execution of clinical studies, including protocol development, study reports, and regulatory submissions (IND, BLA)
Lead the translation of preclinical findings into clinical strategy and execution
Build, inspire, and lead high-performing, cross-functional teams (research, regulatory, CMC, clinical operations, IP, etc.) in a dynamic, matrixed environment
Foster a culture of innovation, collaboration, and scientific excellence
Establish and maintain relationships with leading academic collaborators, investigators, and thought leaders in neurology, cell and gene therapy, and translational medicine
Represent BlueRock at key scientific and medical conferences
Establish and maintain collaborative relationships with colleagues at parent company Bayer

Skills

Clinical Development

Neurology

Cell Therapy

Gene Therapy

Stem Cells

Parkinson's Disease

Phase 3 Trials

Regenerative Medicine

Allogeneic Therapy

Pluripotent Stem Cells

BlueRock Therapeutics

Develops advanced cellular therapies for diseases

About BlueRock Therapeutics

BlueRock Therapeutics develops advanced cellular therapies using a unique cell gene platform that directs cellular differentiation and genetically engineers cells. This technology allows them to create new types of medicines aimed at treating complex diseases in areas such as neurology, cardiology, and immunology. Their products work by transforming cells to target specific medical conditions, including neurodegenerative diseases, heart failure, and immune disorders. Unlike many competitors, BlueRock focuses on a specialized approach within the rapidly growing field of regenerative medicine, emphasizing strategic partnerships and research and development to advance their therapies. The company's goal is to address challenging medical conditions through innovative cellular treatments and to generate revenue through collaborations, licensing agreements, and eventual commercialization of their therapies.

Cambridge, MassachusettsHeadquarters

2016Year Founded

$218.9MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Hybrid Work Options

Risks

Competition from established firms like Johnson & Johnson may overshadow BlueRock's innovations.

Reliance on strategic partnerships poses risks if partners shift focus or resources.

Regulatory hurdles could delay product launches, impacting revenue and market position.

Differentiation

BlueRock uses iPSC technology to create novel cellular therapies for complex diseases.

Their strategic partnerships enhance R&D capabilities and expand therapeutic applications.

Focus on neurology, cardiology, and immunology addresses challenging medical conditions.

Upsides

FDA RMAT designation for bemdaneprocel accelerates market entry for Parkinson's therapy.

Successful Phase I trial of bemdaneprocel boosts investor confidence and funding potential.

Collaboration with bit.bio enhances discovery and development of new cell therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free